Mannatech, Incorporated (MTEX)

Mannatech's stock (MTEX) has experienced a notable decline in the past six months. The stock price decreased by 48.53% over the last 12 months, with a year-to-date return of -6.55%. The stock decreased by 12.78% in the past month and 14.33% over the last three months. As of January 9, 2026, the share price was $7.78, a 48.03% decline from $14.98 on January 10, 2025. Key events include the report of financial results for the Third Quarter 2025, showing a net income of $1.9 million, the report of financial results for the Second Quarter 2025, the promotion of Peter Griscom to Chief Operating Officer, the announcement of the results of its Annual Shareholders' Meeting, the premiere of a documentary on marathon legend Steve Edwards, and the report of financial results for the First Quarter 2025, with net sales of $26.6 million.

Direct information on the seasonality of Mannatech's product and service demand is not explicitly detailed, but there is an indication of seasonality in its stock performance. Historically, buying Mannatech Inc (MTEX) stock in August has shown the highest probability of a positive return (58.33%), while February has the lowest probability (25.00%).

Mannatech, Inc. is a global wellness solutions provider that develops, markets, and sells nutritional supplements, topical and skin care products, anti-aging products, and weight-management solutions. The company operates within the health and wellness industry, utilizing a network marketing and e-commerce distribution model. Its major product categories include Integrative Health, Targeted Health, Weight and Fitness, Skin Care, Essentials, and Home, with key products like Ambrotose and TruHealth. The company aims to promote optimal health and well-being through its products and opportunities.

Mannatech, Inc. has an international presence across the Americas, Europe/the Middle East/Africa (EMEA), and Asia/Pacific, with the majority of its revenue generated from the Americas. Its operations include the United States, Canada, and Mexico in the Americas; Austria, the Czech Republic, Denmark, Estonia, Finland, Germany, the Republic of Ireland, Namibia, the Netherlands, Norway, South Africa, Spain, Sweden, the United Kingdom, Belgium, France, Greece, Italy, Luxembourg, and Poland in EMEA; and Australia, Japan, New Zealand, the Republic of Korea, Singapore, Taiwan, Hong Kong, Thailand, and China in Asia/Pacific.

Information specifically detailing Mannatech's brand reputation in the past year is limited. Historically, Mannatech faced challenges around 2007-2008 due to false claims of anti-disease benefits, leading to lawsuits and scrutiny. More recently, Mannatech emphasizes its commitment to scientific innovation and quality, aiming to enhance consumer trust and reinforce its reputation for authenticity and technical expertise. The company also highlights its direct sales model as instrumental in establishing a strong community of users and advocates.

Mannatech, Inc.'s ownership structure includes a significant insider stake, with approximately 49.54% of the company's stock owned by insiders, with J. Stanley Fredrick as the largest individual shareholder. Institutional investors hold a notable position, with 36 institutional owners and shareholders holding a total of 253,052 shares, representing approximately 6.69% to 12.98% of the company's stock. Major institutional owners include BlackRock, Inc., Vanguard Group Inc., and Renaissance Technologies Llc.